The effects of multiple doses of rolofylline on the single-dose pharmacokinetics of midazolam in healthy subjects

American Journal of Therapeutics

Volumn 17, Issue 1, 2010, Pages 53-60

  Stroh, Mark ^a   Dishy, Victor ^a,b   Radziszewski, Waldemar ^a   Hwang, Eunhee ^a,c   Lazarus Shipitofsky, Nicole ^a   Dittrich, Howard ^a   Johnson Levonas, Amy O ^a   Lutz, Ryan ^a   Wagner, John A ^a   Lai, Eseng ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b DAIICHI SANKYO INC   (United States)

^c PFIZER INC   (United States)

Author keywords

Adenosine A1 receptor antagonist; Drug drug interactions; Midazolam; Pharmacokinetics; Rolofylline

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; CYTOCHROME P450 3A4; MIDAZOLAM; ROLOFYLLINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIZZINESS; DOSE RESPONSE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; ENZYME INHIBITION; FATIGUE; FEMALE; HUMAN; HUMAN EXPERIMENT; LABORATORY TEST; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TREATMENT DURATION; URINARY FREQUENCY; VITAL SIGN;

ADOLESCENT; ADULT; AREA UNDER CURVE; CYTOCHROME P-450 CYP3A; DIURETICS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDAZOLAM; MIDDLE AGED; RECEPTOR, ADENOSINE A1; XANTHINES; YOUNG ADULT;

EID: 76149087823     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181c12313     Document Type: Article

References (17)

1. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117: e25-e146.
2. Fonarow GC, Adams KF Jr, Abraham WT, et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005;293:572-580.
3. Nohria A, Mielniczuk LM, Stevenson LW. Evaluation and monitoring of patients with acute heart failure syndromes. Am J Cardiol. 2005;96:32G-40G.
4. Hillege HL, Girbes AR, de Kam PJ, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102:203-210.
5. Heart Failure Society Of America. Evaluation and management of patients with acute decompensated heart failure. J Card Fail. 2006;12:e86-e103.
6. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29:2388-2442.
7. MacFadyen RJ, Gorski JC, Brater DC, et al. Furosemide responsiveness, non-adherence and resistance during the chronic treatment of heart failure: a longitudinal study. Br J Clin Pharmacol. 2004;57:622-631.
8. Cowie MR, Komajda M, Murray-Thomas T, et al. Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH). Eur Heart J. 2006;27:1216-1222.
9. Butler J, Forman DE, Abraham WT, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J. 2004;147:331-338. (Pubitemid 38176835)
10. Vallon V, Muhlbauer B, Osswald H. Adenosine and kidney function. Physiol Rev. 2006;86:901-940.
11. Slawsky MT, Givertz MM. Rolofylline: a selective adenosine 1 receptor antagonist for the treatment of heart failure. Expert Opin Pharmacother. 2009;10:311-322.
12. Dittrich HC, Gupta DK, Hack TC, et al. The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. J Card Fail. 2007; 13:609-617.
13. Givertz MM, Massie BM, Fields TK, et al. The effects of KW-3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol. 2007;50:1551-1560.
14. Chaparro S, Dittrich HC, Tang WH. Rolofylline (KW-3902): a new adenosine A1-receptor antagonist for actue congestive heart failure. Future Cardiol. 2008;4:117-123.
15. Flockhart DA, Tanus-Santos JE. Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch Intern Med. 2002;162:405-412.
16. Food and Drug Administration. Guidance of Industry (draft). Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling. Rockville, MD: Food and Drug Administration, 2006.
17. Klotz U, Arvela P, Rosenkranz B. Effect of single doses of cimetidine and ranitidine on the steady-state plasma levels of midazolam. Clin Pharmacol Ther. 1985;38: 652-655.